Prostatic Cancer Clinical Trials

5 recruiting

Prostatic Cancer Trials at a Glance

10 actively recruiting trials for prostatic cancer are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Montreal, New York, and Haifa. Lead sponsors running prostatic cancer studies include Merck Sharp & Dohme LLC, National Cancer Institute (NCI), and Jiangsu Hansoh Pharmaceutical Co., Ltd..

Browse prostatic cancer trials by phase

Treatments under study

About Prostatic Cancer Clinical Trials

Looking for clinical trials for Prostatic Cancer? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Prostatic Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Prostatic Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting

Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer

Prostate CancerProstatic CancerProstatic Hyperplasia+1 more
National Cancer Institute (NCI)10,000 enrolled1 locationNCT03354416
Recruiting
Phase 1Phase 2

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

MetastasisCastration-Resistant Prostatic Cancer
Merck Sharp & Dohme LLC360 enrolled75 locationsNCT06863272
Recruiting
Phase 2

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals130 enrolled50 locationsNCT07047118
Recruiting
Phase 1Phase 2

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

Metastatic Castration-Resistant Prostatic Cancer
T.O.A.D. Oncology SA180 enrolled4 locationsNCT07258407
Recruiting
Not Applicable

High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer

Prostatic Cancer
University of Nebraska53 enrolled1 locationNCT05754580
Recruiting
Phase 1

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

Breast CancerPancreatic CancerOvarian Cancer+1 more
Jiangsu Hansoh Pharmaceutical Co., Ltd.318 enrolled1 locationNCT05740956
Recruiting
Phase 1Phase 2

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors

Breast CancerPancreatic CancerCancer+7 more
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.188 enrolled1 locationNCT06819215
Recruiting
Phase 3

Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging

Prostatic Cancer, Castration-Resistant
UNICANCER336 enrolled4 locationsNCT06276465
Recruiting
Phase 1

The Bispecific PSMAxCD3 Antibody CC-1 in Patients with Castration Resistant Prostate Carcinoma

Castration-Resistant Prostatic Cancer
University Hospital Tuebingen86 enrolled2 locationsNCT04104607
Recruiting

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

Breast CancerLiver CancerPancreatic Cancer+6 more
University of Sydney300 enrolled4 locationsNCT05184790